{"id":47603,"date":"2016-01-06T12:27:11","date_gmt":"2016-01-06T11:27:11","guid":{"rendered":"https:\/\/www.btitrainingcenter.com\/management-of-androgenetic-alopecia-a-comparative-clinical-study-between-plasma-rich-in-growth-factors-and-topical-minoxidil\/"},"modified":"2026-04-08T16:36:21","modified_gmt":"2026-04-08T15:36:21","slug":"management-of-androgenetic-alopecia-a-comparative-clinical-study-between-plasma-rich-in-growth-factors-and-topical-minoxidil","status":"publish","type":"post","link":"https:\/\/www.btitrainingcenter.com\/it\/management-of-androgenetic-alopecia-a-comparative-clinical-study-between-plasma-rich-in-growth-factors-and-topical-minoxidil\/","title":{"rendered":"Management of androgenetic alopecia: a comparative clinical study between plasma rich in growth factors and topical minoxidil"},"content":{"rendered":"

[vc_row gap=”20″ content_text_aligment=”left” row_background_lines=”no”][vc_column width=”2\/3″][vc_column_text css=””]<\/p>\n

Abstract<\/h3>\n
\n
\n

Background:\u00a0<\/strong>Androgenetic alopecia (AGA) is a common hair disorder. Finasteride and minoxidil have been approved by the Food and Drug Administration (FDA) for the treatment of AGA. However, some side effects have been related to the intake of these drugs. Recently, plasma rich in growth factors has emerged as a safe alternative for the management of pattern hair loss. The purposes of the present study are to evaluate and compare the efficacy and safety of plasma rich in growth factors (PRGFs) versus topical minoxidil treatment in AGA-affected patients.<\/p>\n

Methods:\u00a0<\/strong>Following a retrospective case control design, 379 patients treated with either PRGF or minoxidil were included in this study. Diagnostic trichograms at baseline and 4 months after treatment were performed with the aim of analyzing the anagen\/telogen hair change improvement.<\/p>\n

Results:\u00a0<\/strong>PRGF-treated patients showed higher anagen hair increase improvement compared to minoxidil-treated ones (6.9\u2009\u00b1\u20090.4 and 4.6\u2009\u00b1\u20090.5 %, respectively) (p\u2009<\u20090.05). Telogen hair decrease improvement was also higher in PRGF group (5.7\u2009\u00b1\u20090.3 and 2.6\u2009\u00b1\u20090.5 %, respectively) (p\u2009<\u20090.05). Global photographs showed an overall volume and quality hair improvement for both treatments. No adverse effects were reported.<\/p>\n<\/div>\n

Conclusions:\u00a0<\/strong>This retrospective study shows that PRGF is a safe and effective treatment for AGA and evidences that PRGF exerts improved anagen\/telogen results than topical minoxidil.<\/p>\n

Level of evidence: Level IV, therapeutic study.<\/p>\n<\/div>\n

[\/vc_column_text][vc_empty_space][\/vc_column][vc_column width=”1\/4″ css=”.vc_custom_1775649149693{margin-top: 78px !important;margin-right: 5% !important;margin-left: 30px !important;padding-right: 20px !important;padding-bottom: 20px !important;padding-left: 20px !important;background-color: #F6F6F6 !important;border-radius: 25px !important;}”]

[vc_column_text css=””]Accedi alla brochure di BTI:<\/em>[\/vc_column_text][vc_single_image image=”47530″ img_size=”medium” alignment=”center” onclick=”custom_link” img_link_target=”_blank” css=”” link=”https:\/\/www.btitrainingcenter.com\/wp-content\/uploads\/2021\/08\/1.-USA_Alopecia.pdf”]\n Accedi al pdf<\/span>\n <\/a><\/div><\/div>[\/vc_column][\/vc_row][vc_row][vc_column]\n Accedi all'articolo completo<\/span>\n <\/a>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Eur J Plast Surg 39, 173\u2013180 (2016).<\/strong>
\nAndrogenetic alopecia (AGA) is a common hair disorder. Finasteride and minoxidil have been approved by the Food and Drug Administration (FDA) for the treatment of AGA. However, some side effects have been related to the intake of these drugs. Recently, plasma rich in growth factors has emerged as a safe alternative for the management of pattern hair loss. The purposes of the present study are to evaluate and compare the efficacy and safety of plasma rich in growth factors (PRGFs) versus topical minoxidil treatment in AGA-affected patients.<\/p>\n","protected":false},"author":2002,"featured_media":47530,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[157],"tags":[],"class_list":["post-47603","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-rigenerativa"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/47603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/users\/2002"}],"replies":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/comments?post=47603"}],"version-history":[{"count":3,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/47603\/revisions"}],"predecessor-version":[{"id":47606,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/posts\/47603\/revisions\/47606"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/media\/47530"}],"wp:attachment":[{"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/media?parent=47603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/categories?post=47603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/it\/wp-json\/wp\/v2\/tags?post=47603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}